Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Arcturus Therapeutics Holdings Inc. ARCT

Healthcare  —  Biotechnology
13.85 (0.27) (1.91%) as of 25 Sep
Market cap
$412.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Arcturus Therapeutics Holdings Inc. (ARCT) Business Profile

Updated before January 2025

Company Overview

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a leading clinical-stage biotechnology company specializing in the development of innovative RNA-based medicines. Founded in 2013 and headquartered in San Diego, California, the company has established itself as a pioneer in the field of RNA therapeutics and vaccines. Arcturus leverages its proprietary technologies, including the LUNAR® lipid-mediated delivery system and STARR™ mRNA technology platform, to develop transformative treatments for rare diseases, infectious diseases, and other unmet medical needs.

The company was co-founded by Joseph Payne, who currently serves as the President and Chief Executive Officer. Under his leadership, Arcturus has grown into a globally recognized biotech firm with a strong focus on innovation and collaboration. The company’s leadership team includes experienced professionals with deep expertise in biotechnology, pharmaceuticals, and RNA-based therapies.

Core Business Segments

Arcturus Therapeutics operates primarily in the following core business segments:

RNA Therapeutics

Arcturus is at the forefront of RNA-based medicine, focusing on the development of mRNA therapies for rare genetic diseases. The company’s proprietary STARR™ mRNA technology enables the creation of stable and durable RNA-based treatments. Key products in this segment include:

  • ARCT-810: A therapeutic candidate for the treatment of Ornithine Transcarbamylase (OTC) deficiency, a rare genetic disorder.
  • ARCT-032: A preclinical candidate targeting cystic fibrosis, leveraging the company’s RNA delivery expertise.

Vaccines

Arcturus has made significant strides in the development of mRNA-based vaccines, particularly for infectious diseases. The company’s LUNAR® delivery system enhances the stability and efficacy of its vaccine candidates. Notable products include:

  • ARCT-154: A next-generation COVID-19 vaccine candidate designed to provide broad protection against multiple variants.
  • ARCT-165: Another COVID-19 vaccine candidate under development, focusing on global immunization efforts.

Platform Licensing and Partnerships

Arcturus collaborates with leading pharmaceutical companies and research institutions to license its proprietary technologies. These partnerships generate revenue and expand the application of its RNA delivery and mRNA platforms. Key collaborations include partnerships with Vinbiocare, Janssen Pharmaceuticals, and the Singapore Economic Development Board.

Business Model

Arcturus Therapeutics employs a hybrid business model that integrates proprietary product development with strategic partnerships. The company generates revenue through:

  1. Product Development: Developing and commercializing its own RNA-based therapies and vaccines.
  2. Licensing Agreements: Licensing its LUNAR® and STARR™ platforms to other biotech and pharmaceutical companies.
  3. Collaborative Research: Partnering with global organizations to co-develop innovative treatments.

This diversified approach allows Arcturus to mitigate risks associated with drug development while maximizing the potential of its proprietary technologies.

Strategic Direction

Arcturus is committed to advancing its pipeline of RNA-based therapies and vaccines while exploring new opportunities for growth. Key strategic priorities include:

  • Pipeline Expansion: Accelerating the development of existing candidates like ARCT-810 and ARCT-154 while identifying new therapeutic areas.
  • Global Reach: Expanding its presence in international markets through partnerships and regulatory approvals.
  • Sustainability Goals: Incorporating environmentally sustainable practices in its operations and supply chain.
  • Innovation: Investing in research and development to enhance its LUNAR® and STARR™ platforms.

Competitive Landscape

Arcturus operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Moderna, Inc.: A leader in mRNA-based vaccines and therapeutics.
  • BioNTech SE: Known for its COVID-19 vaccine developed in collaboration with Pfizer.
  • CureVac N.V.: Specializing in mRNA technology for vaccines and therapies.
  • Alnylam Pharmaceuticals: A pioneer in RNA interference (RNAi) therapeutics.

Despite the competition, Arcturus differentiates itself through its proprietary technologies and focus on rare diseases.

Risk Factors

Arcturus faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The development and approval of RNA-based therapies are subject to stringent regulatory requirements.
  • Market Dependence: Reliance on a limited number of product candidates and partnerships for revenue generation.
  • Supply Chain Disruptions: Potential delays in the manufacturing and distribution of its products.
  • Competition: Intense competition from larger, well-funded biotech companies.
  • Clinical Trial Risks: Uncertainty surrounding the outcomes of clinical trials for its therapeutic candidates.

Recent Developments

Arcturus has achieved several milestones in recent years, including:

  • COVID-19 Vaccine Development: Advancing its ARCT-154 and ARCT-165 vaccine candidates to late-stage clinical trials.
  • Partnerships: Strengthening collaborations with global organizations to expand its pipeline and market reach.
  • Regulatory Approvals: Securing Emergency Use Authorization (EUA) for its COVID-19 vaccine candidates in select countries.
  • Technological Innovations: Enhancing its LUNAR® and STARR™ platforms to improve the efficacy and stability of its RNA-based products.

Investment Considerations

Strengths

  • Proprietary technologies with broad applications in RNA therapeutics and vaccines.
  • Strong pipeline of innovative products targeting unmet medical needs.
  • Strategic partnerships with leading pharmaceutical companies.
  • Experienced leadership team with a proven track record.

Risks

  • High dependence on the success of a limited number of product candidates.
  • Regulatory and clinical trial uncertainties.
  • Intense competition in the biotechnology sector.
  • Potential supply chain disruptions.

Conclusion

Arcturus Therapeutics Holdings Inc. is a dynamic player in the biotechnology industry, leveraging its proprietary RNA technologies to address critical healthcare challenges. With a robust pipeline, strategic partnerships, and a commitment to innovation, the company is well-positioned for future growth. However, investors should carefully consider the associated risks, including regulatory hurdles and market competition, before making investment decisions.